title: Aurintricarboxylic acid increases yield of HSV-1 vectors.
abstract: Production of large quantities of viral vectors is crucial for the success of gene therapy in the clinic. There is a need for higher titers of herpes simplex virus-1 (HSV-1) vectors both for therapeutic use as well as in the manufacturing of clinical grade adeno-associated virus (AAV) vectors. HSV-1 yield increased when primary human fibroblasts were treated with anti-inflammatory drugs like dexamethasone or valproic acid. In our search for compounds that would increase HSV-1 yield, we investigated another anti-inflammatory compound, aurintricarboxylic acid (ATA). Although ATA has been previously shown to have antiviral effects, we find that low (micromolar) concentrations of ATA increased HSV-1 vector production yields. Our results showing the use of ATA to increase HSV-1 titers have important implications for the production of certain HSV-1 vectors as well as recombinant AAV vectors.
authors.affiliation: Gene Therapy, Sanofi-Genzyme R&D Center , Framingham, Massachusetts, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Pechan
authors.affiliation: Gene Therapy, Sanofi-Genzyme R&D Center , Framingham, Massachusetts, USA.
authors.forename: Jeffery
authors.initials: J
authors.lastname: Ardinger
authors.affiliation: Gene Therapy, Sanofi-Genzyme R&D Center , Framingham, Massachusetts, USA.
authors.forename: Jyothi
authors.initials: J
authors.lastname: Ketavarapu
authors.affiliation: Gene Therapy, Sanofi-Genzyme R&D Center , Framingham, Massachusetts, USA.
authors.forename: Hillard
authors.initials: H
authors.lastname: Rubin
authors.affiliation: Gene Therapy, Sanofi-Genzyme R&D Center , Framingham, Massachusetts, USA.
authors.forename: Samuel C
authors.initials: SC
authors.lastname: Wadsworth
authors.affiliation: Gene Therapy, Sanofi-Genzyme R&D Center , Framingham, Massachusetts, USA.
authors.forename: Abraham
authors.initials: A
authors.lastname: Scaria